NCT01597648View on ClinicalTrials.gov

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Infection, Human Immunodeficiency Virus I
Interventions
DRUG

Maraviroc

300 mg

DRUG

Combivir

1 tablet: lamivudine 150mg, zidovudine 300mg

DRUG

GSK2838510

Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY